Health Trials

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

ConditionLimited Stage Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University

About this trial

The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.

Eligibility criteria

Qualifiers

None

Disqualifiers

Histologically or cytologically diagnosed mixed small cell lung cancer or non-small cell lung cancer.

Extensive-stage small cell lung cancer.

Has malignant pleural or pericardial effusion.

Previously received systemic anti-tumor therapy for SCLC or anti-tumor therapy with immune checkpoint inhibitors.

Trial design

Treatments tested in this trial

  • Sugemalimab
  • Placebo

Treatment groups

346 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov